The University of Melbourne, Parkville, VIC, Australia.
Liver Int. 2014 Apr;34(4):576-82. doi: 10.1111/liv.12278. Epub 2013 Aug 15.
BACKGROUND & AIMS: Volatile anaesthetic drug-induced liver injury can range from asymptomatic alanine transaminase elevations to fatal hepatic necrosis. There is very limited research regarding hepatotoxicity of modern volatile anaesthetic agents. The aim of this study was to determine how common liver injury consistent with volatile anaesthetic hepatitis is, following exposure to isoflurane, desflurane and sevoflurane; and to propose risk factors for its development.
Following ethics approval, we conducted a retrospective audit of adult trauma patients with abnormal liver biochemistry following volatile anaesthesia during January 1 to December 31, 2009. The data collected included patient demographics, volatile anaesthetic administration, concurrent medication, perioperative liver biochemistry results and comorbidities. The Council for International Organisations of Medical Sciences/Roussel Uclaf Causality Assessment Method scoring system was used to group cases according to the likelihood of volatile anaesthetic being the causative agent of drug-induced hepatotoxicity.
Forty-seven (3%) of 1556 patients had abnormal post-operative liver biochemistry potentially attributable to volatile anaesthetic. Of the 47, 12 patients (26%) had peak alanine transaminase levels greater than 200 U/L. No significant predictors of volatile anaesthetic drug-induced liver injury following isoflurane, desflurane or sevoflurane anaesthesia could be identified.
Volatile anaesthetic drug-induced liver injury in adult trauma patients may be significantly more common than previously noted. This study suggests that about a quarter of patients with volatile anaesthetic drug-induced liver injury develop significant liver injury. Further prospective studies are required to define risk factors and clinical outcomes.
挥发性麻醉药物引起的肝损伤范围从无症状的丙氨酸转氨酶升高到致命性肝坏死。关于现代挥发性麻醉剂的肝毒性,研究非常有限。本研究旨在确定异氟烷、地氟烷和七氟烷暴露后与挥发性麻醉性肝炎一致的肝损伤的常见程度,并提出其发展的危险因素。
在获得伦理批准后,我们对 2009 年 1 月 1 日至 12 月 31 日期间接受挥发性麻醉后肝功能异常的成年创伤患者进行了回顾性审计。收集的数据包括患者人口统计学、挥发性麻醉剂的使用、同时使用的药物、围手术期肝功能生化结果和合并症。使用国际医学组织理事会/鲁塞尔乌克劳夫因果关系评估方法评分系统根据挥发性麻醉剂是否为药物性肝毒性的致病因素将病例分组。
在 1556 例患者中,有 47 例(3%)的术后肝功能生化检查异常可能归因于挥发性麻醉剂。在这 47 例中,有 12 例(26%)患者的丙氨酸转氨酶峰值超过 200 U/L。无法确定异氟烷、地氟烷或七氟烷麻醉后挥发性麻醉剂肝损伤的显著预测因素。
在成年创伤患者中,挥发性麻醉剂肝损伤可能比以前报道的更为常见。本研究表明,约四分之一的挥发性麻醉剂肝损伤患者会出现严重的肝损伤。需要进一步的前瞻性研究来确定危险因素和临床结果。